Loading
Micropapillary adenocarcinoma is bowel cancer in which some of the tumour grows as tiny clusters of cells floating in empty spaces, with the cells turned inside out so the surface that normally faces the bowel faces outwards instead. It is a pattern that goes with heavier invasion of lymph and blood vessels and more involved lymph nodes, and it is graded and treated like ordinary bowel cancer.
What it is. The 2019 World Health Organization classification of digestive tumours lists micropapillary adenocarcinoma among the histological subtypes of colorectal adenocarcinoma (Nagtegaal 2020). Under the microscope the tumour forms small morula-like nests of cells without a fibrovascular core, sitting in empty lacunar spaces, and the cells show reversed polarity: the apical membrane faces the stroma rather than a lumen, which can be shown by staining for villin or epithelial membrane antigen (Oncol Lett 2021).
How it differs from its parent. The micropapillary component is almost never the whole tumour. Reported proportions range from 5 to 80 percent of a lesion and are usually under 30 percent (J Gastrointest Cancer 2026). Where it is present, tumours show more lymphatic and vascular invasion, a higher ratio of involved to examined lymph nodes and a higher pathological T category than colorectal cancers without it, and more invasion again as the proportion rises (Hum Pathol 2018). KRAS, BRAF and TP53 mutations are described in the pattern and are read as driving invasiveness and the loss of polarity rather than defining a separate disease (J Gastrointest Cancer 2026).
How common it is. In 266 colorectal cancers the pattern was found in 27.8 percent at any extent and in 9.4 percent at 5 percent or more of the tumour (Hum Pathol 2018); in 453 tumours the 5 percent threshold was met in 19.8 percent (Oncol Lett 2021). Counts depend entirely on the threshold used, and no national registry records it.
How it is treated. No trial has been run in this histology. Treated as colorectal adenocarcinoma: resection with adjuvant chemotherapy by stage when removable, the systemic rows of the parent page when not; the parent record carries the trials. The practical consequence of the report is staging: the pattern travels with node involvement, so it is a reason to look carefully at the nodes and the margins rather than a reason to change the drugs.
A pattern rather than a separate tumour in most series. In 266 Korean colorectal cancers a micropapillary pattern of any extent was present in 27.8 percent and made up 5 percent or more of the tumour in 9.4 percent; in a later series of 453 tumours the 5 percent threshold was met in 19.8 percent. No UK or registry count is published.
Right-sided tumours behave differently from left-sided and rectal ones; the colon drains along its mesenteric vessels, the rectum into the mesorectum and pelvic side wall.
Same organ: Colon cancer (adenocarcinoma of the colon), Adenoma-like adenocarcinoma of the colon and rectum, Lynch syndrome-associated colorectal cancer, Familial adenomatous polyposis-associated colorectal cancer, Mucinous adenocarcinoma of the colon and rectum, Signet ring cell carcinoma of the colon and rectum, Medullary carcinoma of the colon, Serrated adenocarcinoma of the colon and rectum, Peritoneal mesothelioma, Colorectal cancer, Rectal cancer, Mismatch-repair deficient (MSI-high) colorectal cancer, BRAF V600E-mutant colorectal cancer, HER2-amplified colorectal cancer, KRAS G12C-mutant colorectal cancer, Early-onset colorectal cancer (under 50), Anal cancer (squamous cell carcinoma), Appendiceal cancer and pseudomyxoma peritonei, Small intestine cancer (small bowel adenocarcinoma), Small intestinal neuroendocrine tumours, Anal high-grade squamous intraepithelial lesions (precursor), Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma, Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei, Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell), Goblet cell adenocarcinoma of the appendix, Localised small bowel adenocarcinoma (stage I to III, resected), Advanced and metastatic small bowel adenocarcinoma
Resection with the usual nodal harvest; adjuvant chemotherapy decided by stage as for colorectal adenocarcinoma of no special type, with the node involvement that travels with this pattern taken into account.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Micropapillary adenocarcinoma of the colon and rectum" OR ABSTRACT:"Micropapillary adenocarcinoma of the colon and rectum" OR TITLE:"Micropapillary adenocarcinoma of the colon and rectum small tumour nests with reversed polarity; heavy lymphatic and vascular invasion" OR ABSTRACT:"Micropapillary adenocarcinoma of the colon and rectum small tumour nests with reversed polarity; heavy lymphatic and vascular invasion" OR TITLE:"Colorectal micropapillary carcinoma" OR ABSTRACT:"Colorectal micropapillary carcinoma" OR TITLE:"Micropapillary colorectal cancer" OR ABSTRACT:"Micropapillary colorectal cancer" OR TITLE:"Colorectal carcinoma with micropapillary pattern" OR ABSTRACT:"Colorectal carcinoma with micropapillary pattern") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Micropapillary adenocarcinoma of the colon and rectum, not a curated reading list.
No targets or pathways are linked to this cancer yet. Browse the gene hub →
Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Bleeding that does not stop by itself, bleeding from more than one site, or new bruising in several places or one large area.
The bowel cancer regimens share low blood counts, tiredness, sickness and a sore mouth. Oxaliplatin adds cold-triggered tingling, irinotecan adds early and late diarrhoea, capecitabine adds hand-foot syndrome and needs a DPD test first, and cetuximab or panitumumab add an acne-like rash and low magnesium. The rule for all of them: ring the 24-hour number rather than wait.
See all on the product pages:CAPOX (capecitabine, oxaliplatin)FOLFOX (5-FU, leucovorin, oxaliplatin)·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Micropapillary adenocarcinoma of the colon and rectum, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.